Oncolytics Biotech® Announces Type C FDA Meeting to Discuss Single-arm Registrational Pathway for Pelareorep in Anal Cancer

Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage immunotherapy company developing pelareorep, an investigational, systemically delivered immunotherapy that has ...
MarketWatch

Praxis Converts Elsunersen Study to Single-Arm Design After FDA Meeting

Praxis Precision Medicines is converting its EMBRAVE3 study of elsunersen for children suffering from a developmental disease into a single-arm study after meeting with the Food and Drug ...
Endovascular Today

Shape Memory Medical Initiates First-in-Human FLAGSHIP Study of False Lumen Embolization System

Shape Memory Medical has announced the first patient enrollments in the FLAGSHIP study, a prospective single-arm open-la ...
TCTMD

HF Benefits Look Durable in Single-Arm Study of Coronary Sinus Shunt

BOSTON, MA—Patients with heart failure and mildly reduced or preserved ejection fraction (HFmrEF/HFpEF) and elevated left atrial pressures appear to derive lasting benefits from a shunt that diverts ...
ascopubs.org

A single-arm IIT study of HA131 (hepatic arterial infusion) in combination with systemic therapy (XELOX with or without bevacizumab) as first-Line treatment in gastrointestinal ...

Liposomal irinotecan plus bevacizumab in irinotecan-refractory metastatic colorectal cancer: A multicenter, phase I/II trial. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This ...
ascopubs.org

LODESTAR: A single-arm phase II study of rucaparib in solid tumors with pathogenic germline or somatic variants in homologous recombination repair genes.

Picking needles in a haystack: Exploring rare variants of a pan-cancer target in the RET landscape from 229,453 adult cancer patients. This is an ASCO Meeting Abstract from the 2025 ASCO Annual ...